WO2012145893A1 - 安它可朋组合物 - Google Patents

安它可朋组合物 Download PDF

Info

Publication number
WO2012145893A1
WO2012145893A1 PCT/CN2011/073297 CN2011073297W WO2012145893A1 WO 2012145893 A1 WO2012145893 A1 WO 2012145893A1 CN 2011073297 W CN2011073297 W CN 2011073297W WO 2012145893 A1 WO2012145893 A1 WO 2012145893A1
Authority
WO
WIPO (PCT)
Prior art keywords
sds
pvp
composition
ampicone
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2011/073297
Other languages
English (en)
French (fr)
Inventor
郝为华
王钟靓
陈蕙筠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innopharmax Inc
Original Assignee
Innopharmax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innopharmax Inc filed Critical Innopharmax Inc
Priority to BR112013027219A priority Critical patent/BR112013027219A2/pt
Priority to CN201180070146.8A priority patent/CN103476406B/zh
Priority to EA201301197A priority patent/EA025627B1/ru
Priority to EP11864150.5A priority patent/EP2702991A4/en
Priority to US14/114,032 priority patent/US20140120166A1/en
Priority to CA2833443A priority patent/CA2833443C/en
Priority to AU2011366717A priority patent/AU2011366717B2/en
Priority to KR1020137028892A priority patent/KR101807907B1/ko
Priority to PCT/CN2011/073297 priority patent/WO2012145893A1/zh
Priority to JP2014506709A priority patent/JP5855230B2/ja
Priority to MX2013012429A priority patent/MX2013012429A/es
Publication of WO2012145893A1 publication Critical patent/WO2012145893A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Definitions

  • This invention relates to an Entacapone composition comprising acecophan, PVP K30 and SDS. Furthermore, the invention relates to a process for the preparation of the ampicone composition and to its use. Background technique
  • Anecone is (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-indole, fluorene-diethyl-2-acrylamide ((E)- 2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-2-propenamide) is a drug currently known to be useful in the treatment of Parkinson's Disease.
  • the currently known ampoule compositions are mostly made into smaller particles by grinding or pulverization to improve the dissolution rate and the body.
  • availability for example, US 2010/0104634 A1 is such that 90% of the Angkor particles have a particle size of less than 40 ⁇ m, and WO 2009098661 A1 is a micronized process of particles of anaconone and sugar alcohol to make the particle size smaller than 30 ⁇ .
  • the inventors have developed an improved method capable of improving the elution rate of anaconone without pulverizing, pulverizing or micronizing, and simplifying the process to increase the yield and reduce the production cost. .
  • One of the objects of the present invention is to provide an ampicone composition
  • an ampicone composition comprising acecophan or a pharmaceutical thereof Acceptable salts, PVP K30 (Polyvinylpyrrolidone® 30), SDS (sodium dodecyl sulfate), and at least one pharmaceutically acceptable excipient.
  • the present invention provides an ampicone composition
  • the mass ratio of the Antecone: PVP K30: SDS is 1: 0.05-0. 2: 0.06; more preferably, the mass thereof.
  • the ratio is 1: 0.2: 0.06.
  • the ampacic composition has a dissolution rate greater than 90%; more preferably, the dissolution rate is greater than 95%.
  • the ampic composition comprises at least one excipient, and the excipient is selected from the group consisting of Povidone and crospovidone. (Crospovidone), saccharide, Croscarmellose Sodium, or a combination thereof.
  • the saccharide may, for example, be selected from the group consisting of Microcrystalline Cellulose (MCC), Mannitol, Cellulose, Hydroxypropyl Methylcellulose, Starch or Lactose.
  • the present invention also provides a process for the preparation of an ampicone composition as hereinbefore described, which comprises the following steps:
  • step (c) granulating the mixture obtained in step (b);
  • step (d) drying the granules obtained in step (c) until the moisture content is between 1% and 3%, resulting in the acetonide composition;
  • the above method does not include a grinding, pulverizing or micronizing step of making a mixture of acesulfame or a pharmaceutically acceptable salt thereof, a mixture of PVP K30 and SDS having a particle diameter of less than 30 ⁇ m.
  • the mass ratio of PVP K30: SDS in the method step (a) is 1: 0.05-0.2: 0.06; more preferably, the mass ratio is 1 : 0.2: 0.06.
  • the method step (granulation of c is wet granulation).
  • the method does not comprise milling, comminuting or micronizing the particle size of the mixture of anesthenate or a pharmaceutically acceptable salt thereof, a mixture of PVP K30 and SDS of less than 40 ⁇ m.
  • the method (a) further comprises at least one shaping, and the excipient is selected from the group consisting of povidone, crospovidone, and saccharide. , croscarmellose sodium, or a combination thereof.
  • the saccharide may, for example, be selected from the group consisting of microcrystalline cellulose, mannitol, cellulose, hydroxypropylmethylcellulose, starch or lactose.
  • the present invention further provides a pharmaceutical composition comprising an ampicone composition as hereinbefore described; preferably, a pharmaceutical composition for treating Parkinson's disease.
  • the pharmaceutical composition further comprises left dopa
  • the invention further provides the use of an ampicone composition as hereinbefore described for the preparation of a pharmaceutical composition; preferably, for the preparation of a pharmaceutical composition for the treatment of Parkinson's disease.
  • the pharmaceutical composition prepared by the use comprises a mixture of levodopa and hydroxybenzidine, or further comprises levodopa and carbidopa.
  • the ampicone composition provided by the present invention can increase the elution rate of the ancanone to more than 88% without the need of grinding, pulverizing or micronizing, compared with the conventional method.
  • the process is simplified, and the risk of deterioration of the safety is not caused by the high heat caused by the grinding-related steps, and the yield is improved and the cost is lowered.
  • MCC, SDS, PVP K30, mannitol and acetonide were mixed sequentially for 5 minutes, after which the mixture powder was passed through a 150 ⁇ m (100 mesh) sieve; the sieved powder was poured into a granulator. Spray deionized water for granulation. The obtained granules are dried in an oven at 50 ° C until the moisture content is between 1% and 3%, and then filled into capsules or ingots to obtain an enamel composition 1 to 6.
  • the drug solvate method for the acecoin is retrieved according to the Dissolution Methods Database provided on the FDA website (http: ⁇ www. accessdata.fda.gov/scripts/ cder/dissolution/dsp—SearchResults— Dissolutions. cfm ) Perform a dissolution test in which the dissolution is performed using a USP standard paddle device at a speed of 50 rpm and a solvent of 900 mL of a pH 5.5 phosphate buffer solution for a test time of 120 minutes. The analysis was carried out by HPLC, and the obtained elution rate is shown in Table 2 below. Table 2
  • the elution rate of Ankekeone itself is about 81.15%.
  • the mass ratio of PVP K30: SDS is 1: 0.05-0.6: 0.06 ⁇ 0.1, the resulting combination is acceptable.
  • the dissolution rate of the substance is greatly increased, up to 88%; when the mass ratio of PVP K30: SDS is 1: 0.05-0.2: 0.06, the dissolution rate of the obtained Anitapeng composition can be More than 90%; and when the PVP K30: SDS mass ratio is 1: 0.2: 0.06, its dissolution rate can reach more than 95%.
  • the use of the above ratio in the case of a process such as grinding, pulverization or micronization does not only have the advantages of high elution rate, simple process, etc., but also does not cause high heat due to grinding. It can be a doubt about peer deterioration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Description

安它可朋组合物 技术领域
本发明是关于一种安它可朋 （Entacapone) 组合物， 其包含安它可朋、 PVP K30及 SDS。 此外， 本发明亦关于所述安它可朋组合物的制备方法及其 用途。 背景技术
安它可朋即 (E)-2-氰基 -3-(3,4-二羟基 -5-硝基-苯基) -Ν,Ν-二乙基 -2-丙烯酰 胺 ((E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-2-propenamide)， 是目前已知可用于治疗帕金森氏症 （Parkinson's Disease) 的药物。
由于安它可朋的溶离率及生体可用率低， 目前已知的安它可朋组合物多 以研磨或粉碎的方式将之制成尺寸较小的颗粒， 以提高其溶离率及生体可用 率。举例来说， US 2010/0104634 A1是使 90%的安它可朋颗粒粒径小于 40μπι， 而 WO 2009098661 A1则是将安它可朋与糖醇的颗粒经微粒化工艺而使其粒 径小于 30μπι。
然而， 研磨或微粒化这类工艺往往会产生高热， 而使药物变质， 另外， 此类工艺仍有产率低及成本高的问题。 因此， 如何在毋须研磨、 粉碎或微粒 化等工艺的情况下制备出溶离率或生体可用率高的安它可朋组合物， 是业界 亟待解决的课题。 发明内容
为解决上述问题， 发明人开发出一种改良方法， 能够在毋须研磨、 粉碎 或微粒化等工艺的情况下提高安它可朋的溶离率， 并使工艺简化以提高产率 及降低生产成本。
本发明目的之一是提供一种安它可朋组合物， 其包含安它可朋或其医药 可接受盐、 PVP K30 ( Polyvinylpyrrolidone Κ30)、 SDS ( sodium dodecyl sulfate) , 以及至少一种医药上可接受的赋形剂。
为达上述目的， 本发明提供了一种安它可朋组合物， 其包含安它可朋或 其医药可接受盐、 PVP K30及 SDS; 其中安它可朋： PVP K30: SDS的质量 比为 1 : 0.05-0.6： 0.06-0.1 , 且其溶离率大于 88%。
在本发明的较佳实施态样中， 所述安它可朋组合物中的安它可朋： PVP K30: SDS的质量比为 1： 0.05-0. 2： 0.06； 更佳者， 其质量比为 1： 0.2： 0.06。
在本发明的较佳实施态样中， 所述安它可朋组合物的溶离率大于 90%; 更佳者， 其溶离率大于 95%。
在本发明的较佳实施态样中， 所述安它可朋组合物进一歩包含至少一种 赋形剂，且所述赋形剂是选自聚维酮（ Povidone )、交联聚维酮（ Crospovidone )、 糖类、 交联羧甲基纤维素钠 （Croscarmellose Sodium) ， 或其组合。 所述糖 类例如可选自微晶纤维素 （Microcrystalline Cellulose , MCC ) 、 甘露糖醇 (Mannitol)、纤维素、羟丙基甲基纤维素（ Hydroxypropyl Methylcellulose ) 、 淀粉或乳糖。
本发明还提供了一种如前文所述的安它可朋组合物的制备方法， 其包含 下列歩骤：
(a) 将安它可朋或其医药可接受盐、 PVP K30及 SDS混合，其中安它可 朋： PVP K30: SDS的质量比为 1 : 0.05-0.6： 0.06-0.1； (b) 使歩骤 所得的混合物通过筛网， 且该筛网的网目在 180μπι以下， 更佳者， 在 150μπι以下；
(c) 将歩骤 (b)所得的混合物进行造粒；
(d) 将歩骤 (c所得的颗粒烘干， 直至水分含量介于 1%~3%， 得出所述 的安它可朋组合物；
以上方法不包含使安它可朋或其医药可接受盐、 PVP K30及 SDS的混合 物的粒径小于 30μπι的研磨、 粉碎或微粒化歩骤。 在本发明的较佳实施态样中，所述方法歩骤 (a)中的安它可朋： PVP K30: SDS的质量比为 1 : 0.05-0.2： 0.06； 更佳者， 其质量比为 1 : 0.2： 0.06。
在本发明的较佳实施态样中， 所述方法歩骤 (c 的造粒为湿式造粒。
在本发明的较佳实施态样中， 所述方法不包含使安它可朋或其医药可接 受盐、 PVP K30及 SDS的混合物的粒径小于 40μπι的研磨、 粉碎或微粒化歩 骤。
在本发明的较佳实施态样中， 所述方法歩骤 (a)进一歩包含至少一种赋形 齐 1J , 且所述赋形剂选自聚维酮、 交联聚维酮、 糖类、 交联羧甲基纤维素钠， 或其组合。 所述糖类例如可选自微晶纤维素、 甘露糖醇、 纤维素、 羟丙基甲 基纤维素、 淀粉或乳糖。
本发明另提供一种医药组合物， 其包含如前文所述的安它可朋组合物； 较佳者， 是治疗帕金森氏症的医药组合物。
在本发明的较佳实施态样中， 所述医药组合物进一歩包含左多巴
(Levodopa) 及羟苯丝肼 （ Benserazide ) 、 或进一歩包含左多巴及卡比多巴 (Carbidopa) 。
本发明又提供一种将如前文所述的安它可朋组合物用于制备医药组合物 的用途； 较佳者， 是用于制备治疗帕金森氏症的医药组合物。
在本发明的较佳实施态样中， 所述用途所制备的医药组合物进一歩包含 左多巴及羟苯丝肼、 或进一歩包含左多巴及卡比多巴。
由上可知， 本发明所提供的安它可朋组合物可在毋须研磨、 粉碎或微粒 化等工艺的情况下将安它可朋的溶离率提高到 88%以上， 与习知方法相较之 下， 不但省略研磨相关歩骤而简化工艺， 同时不会因为研磨相关歩骤而导致 高热而引发安它可朋变质的风险， 亦可使产率提高， 成本降低。 具体实施方式
下列实施例仅为最佳实施态样的例示， 非意图限制本发明的范围。 所属 领域的技术人员可藉由本发明的揭露， 在不背离本发明的精神的范围内做出 适度的变更和修正。 实施例
首先依照下表 1的组合物配比， 制得安它可朋组合物 1~6的颗粒。
将 MCC、 SDS、 PVP K30、 甘露糖醇及安它可朋依序混合 5分钟， 之后 使混合物粉末通过 150μπι ( 100 目） 的筛网； 再将通筛后的粉末倒入造粒机 中， 喷洒去离子水， 以进行造粒。 所得颗粒置于 50°C烘箱中烘干， 直至水分 含量介于 1%~3%， 之后充入胶囊或是打锭， 得出安它可朋组合物 1~6。
表 1
Figure imgf000005_0001
依据在 FDA网站上提供的溶离方法数据库 ( Dissolution Methods Database) 中检索得到安它可朋的药物溶离方法 （http：〃 www. accessdata.fda.gov/scripts/ cder/dissolution/dsp—SearchResults— Dissolutions. cfm ) 进行溶离试验， 其中溶 离是使用 USP标准搅拌桨式装置 (paddle) ,转速为 50 rpm，所用溶媒为 900mL 的 pH5.5的磷酸缓冲溶液，试验时间为 120分钟，之后利用 HPLC进行分析， 所得溶离率如下表 2所示。 表 2
Figure imgf000006_0001
由上可知， 安它可朋本身的溶离率大约是 81.15%， 当安它可朋： PVP K30: SDS的质量比为 1 : 0.05-0.6： 0.06~0.1之时， 所得安它可朋组合物的 溶离率大幅增加， 可达 88%以上； 当安它可朋： PVP K30: SDS的质量比为 1： 0.05-0.2： 0.06之时， 所得安它可朋组合物的溶离率可达 90%以上； 而当 安它可朋： PVP K30: SDS的质量比为 1 : 0.2： 0.06时， 其溶离率可达 95% 以上。 因此， 利用上述配比在毋须研磨、 粉碎或微粒化等工艺的情况下所得出 的安它可朋组合物不但具有溶离率高、 工艺简便等优点， 亦没有因为研磨时 产生高热而导致安它可朋变质的疑虑。

Claims

权利要求书
1. 一种安它可朋组合物， 其包含安它可朋或其医药可接受盐、 PVP K30 及 SDS; 其中安它可朋： PVP K30: SDS 的质量比为 1 : 0.05~0.6： 0.06-0.1 , 且其溶离率大于 88%。
2. 如权利要求 1所述的安它可朋组合物， 其中安它可朋： PVP K30: SDS 的质量比为 1 : 0.05-0.2： 0.06。
3. 如权利要求 2所述的安它可朋组合物， 其中安它可朋： PVP K30: SDS 的质量比为 1 : 0.2: 0.06。
4. 如权利要求 1所述的安它可朋组合物， 其溶离率大于 90%。
5. 如权利要求 4所述的安它可朋组合物， 其溶离率大于 95%。
6. 如权利要求 1所述的安它可朋组合物， 其进一歩包含至少一种赋形剂， 且所述赋形剂选自聚维酮、 交联聚维酮、 糖类、 交联羧甲基纤维素钠， 或其组合。
7. 如权利要求 6所述的安它可朋组合物， 其中糖类选自微晶纤维素、 甘 露糖醇、 纤维素、 羟丙基甲基纤维素、 淀粉或乳糖。
8. 一种如权利要求 1所述的安它可朋组合物的制备方法， 其包含下列歩 骤：
(a) 将安它可朋或其医药可接受盐、 PVP K30及 SDS混合， 其中安它 可朋： PVP K30: SDS的质量比为 1 : 0.05-0.6： 0.06-0.1；
(b) 使歩骤 所得的混合物通过筛网，且该筛网的网目在 180μπι以下；
(c) 将歩骤 (b)所得的混合物进行造粒；
(d) 将歩骤 (c所得的颗粒烘干， 直至水分含量介于 1%~3%， 得出如权 利要求 1所述的安它可朋组合物；
以上方法不包含使安它可朋或其医药可接受盐、 PVP K30及 SDS的混 合物的粒径小于 30μπι的研磨、 粉碎或微粒化歩骤。
9. 如权利要求 8所述的方法， 其中歩骤 的安它可朋： PVP K30: SDS 的质量比为 1 : 0.05-0.2： 0.06。
10.如权利要求 9所述的方法， 其中歩骤 (a)的安它可朋： PVP K30: SDS 的质量比为 1 : 0.2: 0.06。
11.如权利要求 8所述的方法， 其中歩骤c 的造粒为湿式造粒。
12.如权利要求 8所述的方法， 其不包含使安它可朋或其医药可接受盐、 PVP K30及 SDS的混合物的粒径小于 40μπι的研磨、 粉碎或微粒化歩 骤。
13.如权利要求 8所述的方法， 其中所述歩骤 进一歩包含至少一种赋形 剂， 且所述赋形剂是选自聚维酮、 交联聚维酮、 糖类、 交联羧甲基纤 维素钠， 或其组合。
14.如权利要求 13所述的方法，其中所述糖类选自微晶纤维素、甘露糖醇、 纤维素、 羟丙基甲基纤维素、 淀粉或乳糖。
15.—种医药组合物， 其包含如权利要求 1所述的安它可朋组合物。
16.如权利要求 15所述的医药组合物，其是治疗帕金森氏症的医药组合物。
17.如权利要求 16所述的医药组合物， 其进一歩包含左多巴及羟苯丝肼、 或进一歩包含左多巴及卡比多巴。
18.—种将如权利要求 1所述的安它可朋组合物用于制备医药组合物的用 途。
19.如权利要求 18所述的用途， 其中所述医药组合物为治疗帕金森氏症的 医药组合物。
20.如权利要求 18所述的用途， 其中所述医药组合物进一歩包含左多巴及 羟苯丝肼、 或进一歩包含左多巴及卡比多巴。
PCT/CN2011/073297 2011-04-26 2011-04-26 安它可朋组合物 Ceased WO2012145893A1 (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BR112013027219A BR112013027219A2 (pt) 2011-04-26 2011-04-26 composição de entacapone, processo para preparar a composição de entacapone, composição farmacêutica, e, uso da composição de entacapone
CN201180070146.8A CN103476406B (zh) 2011-04-26 2011-04-26 安它可朋组合物
EA201301197A EA025627B1 (ru) 2011-04-26 2011-04-26 Композиция для лечения болезни паркинсона
EP11864150.5A EP2702991A4 (en) 2011-04-26 2011-04-26 COMPOSITION OF ENTACOPONE
US14/114,032 US20140120166A1 (en) 2011-04-26 2011-04-26 Composition of entacopone
CA2833443A CA2833443C (en) 2011-04-26 2011-04-26 A composition of entacapone
AU2011366717A AU2011366717B2 (en) 2011-04-26 2011-04-26 A composition of entacopone
KR1020137028892A KR101807907B1 (ko) 2011-04-26 2011-04-26 엔타카폰의 조성물
PCT/CN2011/073297 WO2012145893A1 (zh) 2011-04-26 2011-04-26 安它可朋组合物
JP2014506709A JP5855230B2 (ja) 2011-04-26 2011-04-26 エンタカポン組成物
MX2013012429A MX2013012429A (es) 2011-04-26 2011-04-26 Una composicion de entacopone.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/073297 WO2012145893A1 (zh) 2011-04-26 2011-04-26 安它可朋组合物

Publications (1)

Publication Number Publication Date
WO2012145893A1 true WO2012145893A1 (zh) 2012-11-01

Family

ID=47071548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/073297 Ceased WO2012145893A1 (zh) 2011-04-26 2011-04-26 安它可朋组合物

Country Status (11)

Country Link
US (1) US20140120166A1 (zh)
EP (1) EP2702991A4 (zh)
JP (1) JP5855230B2 (zh)
KR (1) KR101807907B1 (zh)
CN (1) CN103476406B (zh)
AU (1) AU2011366717B2 (zh)
BR (1) BR112013027219A2 (zh)
CA (1) CA2833443C (zh)
EA (1) EA025627B1 (zh)
MX (1) MX2013012429A (zh)
WO (1) WO2012145893A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101974752B1 (ko) * 2017-12-31 2019-09-05 황혜미 욕창 치료용 크림 및 이를 제조하는 방법
WO2021182981A1 (en) * 2020-03-13 2021-09-16 BIAL - PORTELA & Cª, S.A. Micronised opicapone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1319005A (zh) * 1998-09-14 2001-10-24 欧里恩公司 含有恩他卡朋和硝替卡朋以及交联纤维素衍生物的药物组合物
CN1654037A (zh) * 2004-02-13 2005-08-17 马晶 一种枸橼酸他莫昔芬分散片及其制法
WO2009098661A1 (en) 2008-02-06 2009-08-13 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
US20100104634A1 (en) 2006-12-27 2010-04-29 Mahesh Rameshwar Kalantri Pharmaceutical compositions of entacapone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
AU2256702A (en) * 2000-12-01 2002-06-11 Kyowa Hakko Kogyo Kk Composition improved in solubility or oral absorbability
US20050003001A1 (en) * 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments
PL1896006T3 (pl) * 2005-06-08 2010-03-31 Orion Corp Sposób wytwarzania granulek zawierających entakapon do postaci dawkowania doustnego
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
CA2734972C (en) * 2008-08-22 2017-03-28 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
US9750702B2 (en) * 2009-12-25 2017-09-05 Innopharmax, Inc. Pharmaceutical composition for treating parkinson's disease and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1319005A (zh) * 1998-09-14 2001-10-24 欧里恩公司 含有恩他卡朋和硝替卡朋以及交联纤维素衍生物的药物组合物
CN1654037A (zh) * 2004-02-13 2005-08-17 马晶 一种枸橼酸他莫昔芬分散片及其制法
US20100104634A1 (en) 2006-12-27 2010-04-29 Mahesh Rameshwar Kalantri Pharmaceutical compositions of entacapone
WO2009098661A1 (en) 2008-02-06 2009-08-13 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2702991A4

Also Published As

Publication number Publication date
EP2702991A4 (en) 2015-02-18
CA2833443A1 (en) 2012-11-01
CA2833443C (en) 2017-11-07
JP2014512395A (ja) 2014-05-22
KR101807907B1 (ko) 2017-12-11
CN103476406A (zh) 2013-12-25
CN103476406B (zh) 2017-05-24
US20140120166A1 (en) 2014-05-01
MX2013012429A (es) 2013-12-06
EP2702991A1 (en) 2014-03-05
AU2011366717A1 (en) 2013-11-07
KR20140024879A (ko) 2014-03-03
JP5855230B2 (ja) 2016-02-09
AU2011366717B2 (en) 2017-06-15
EA025627B1 (ru) 2017-01-30
EA201301197A1 (ru) 2014-02-28
BR112013027219A2 (pt) 2016-12-27

Similar Documents

Publication Publication Date Title
CN104288154B (zh) 一种含有不同粒径范围的法匹拉韦药物组合物
CN105982870A (zh) 一种阿哌沙班片剂
CN104367561B (zh) 一种牛磺熊去氧胆酸制剂的制备方法
CN104666262B (zh) 一种利伐沙班片
CN104887633A (zh) 一种利伐沙班片剂及其制备方法
WO2012145893A1 (zh) 安它可朋组合物
JP6216408B2 (ja) 固体剤形で非常に難溶性の薬物を調製する方法
TWI419685B (zh) 安它可朋組成物
CN106389428B (zh) 一种具有提高阿齐沙坦生物利用度和稳定性的组合物及制备方法
HK1187269A (zh) 安它可朋组合物
HK1187269B (zh) 安它可朋组合物
CN104771380A (zh) 一种快速溶出的他克莫司胶囊
CN106860407A (zh) 一种利伐沙班片
WO2013029198A1 (zh) 阿德福韦酯固体制剂及其制备方法
CN104666260A (zh) 一种依折麦布片剂
CN105287393B (zh) 甲磺酸沙喹那韦三甲基壳聚糖微球及其制备方法
CN104027316B (zh) 一种格列美脲片剂及其制备方法
CN104337783B (zh) 一种卡培他滨片剂及其制备方法
CN103860494B (zh) 阿立哌唑片及其制备方法
CN102670519A (zh) 一种可快速溶出的地诺孕素口服制剂及其制备方法
CN106913542B (zh) 一种普拉格雷片剂及其制备方法
CN106913549A (zh) 一种普拉格雷片剂及其制备方法
CN116602928A (zh) 一种甲苯磺酸艾多沙班组合物和制备方法
CN104523632A (zh) 一种阿齐沙坦片剂
CA2871886A1 (en) Amorphous dispersions of paroxetine mesylate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11864150

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011864150

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2833443

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13252787

Country of ref document: CO

Ref document number: MX/A/2013/012429

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014506709

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137028892

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011366717

Country of ref document: AU

Date of ref document: 20110426

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201301197

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 14114032

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013027219

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013027219

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131022